Heather Vaught, OD
Optometrist · Conway, SCNPI 1235608951
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,548 of the $5,516 with a category attached, or 82.4%. It is spread thinly across 21 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $68.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$1K
- Coopervision Inc.$721
- Bausch & Lomb Americas Inc.$536
- LKC Technologies, Inc.$499
- Optos, Inc.$488
- Sight Sciences, Inc.$406
- plus $2K from 15 others
What the payments were for
- Travel & lodging$71913%
- Food & beverage$4,54882%
- Entertainment$2495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 11 | $1,018 |
| Coopervision Inc. | 10 | $721 |
| Bausch & Lomb Americas Inc. | 7 | $536 |
| LKC Technologies, Inc. | 5 | $499 |
| Optos, Inc. | 6 | $488 |
| Sight Sciences, Inc. | 5 | $406 |
| Amgen(2 entities) | 3 | $307 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $242 |
| AbbVie(2 entities) | 7 | $240 |
| Oyster Point Pharma, Inc. | 4 | $202 |
| Biotissue Holdings Inc. | 3 | $184 |
| Notal Vision, Inc. | 3 | $147 |
| Tarsus Pharmaceuticals, Inc. | 2 | $143 |
| Astellas Pharma US Inc | 1 | $124 |
| Dompe US, Inc. | 2 | $74 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Carl Zeiss Meditec USA, Inc. | 1 | $37 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Alcon | 1 | $22 |
| Harrow Eye, LLC | 1 | $20 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$844
- PANORAMIC OPHTHALMOSCOPE$559
- OCT OPHTHALMOSCOPE$405
- NFC-700$280
- MIEBO$244
- XIIDRA$244
- MyDay Contact Lens$234
- TEPEZZA$219
- OMNI(R) SURGICAL SYSTEM (US)$140
- TYRVAYA$138
- TEARCARE SYSTEM$136
- XDEMVY$125
- INFUSE$124
- Izervay$124
- INFUSE MULTIFOCAL$121
- Multiple Brands Contact Lens$118
How this compares
$5,516 in reported general payments places this provider in the 90th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $24,805 |
| LumiganBimatoprost | 18 | $9,477 |
| TyrvayaVarenicline Tartrate | 11 | $8,289 |
| Latanoprost | 197 | $1,656 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $562 |
| Timolol Maleate | 52 | $536 |
| Prednisolone Acetate | 13 | $509 |
| ValacyclovirValacyclovir Hcl | 12 | $481 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $386 |
| ErythromycinErythromycin Base | 15 | $188 |
| Brimonidine Tartrate | 13 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $240 | $34,28343 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $202 | $8,28911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Conway
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
- Scott OliverRock Hill$16K
- Michael CriswellMount Pleasant$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.